US IPO Pipeline SEC S-1 Filings — September 03, 2026

Filing to resell 5.1M shares (~64% of post-issuance shares) creates severe dilution risk; the company has negative working capital of ~$131M and burned $9.8M in operating cash over six months

The Series B Preferred Stock has a $50,000 per share liquidation preference, subordinating common shareholders entirely. Combined with a stockholders' deficit of $19M, common equity is effectively worthless in any downside scenario

Common Warrants have an exercise price of $266.25, far above trading range. Cashless exercise provides zero proceeds to the company, signaling the warrants are unlikely to provide capital relief

Filed S-1 for a $15M committed equity facility while simultaneously facing a Nasdaq delisting hearing (Sept 1, 2026) for both bid price and equity deficiencies. Stockholders' equity of $1.52M is 39% below the $2.5M minimum

Accumulated deficit of $109.2M, negative working capital of $1.7M, and a going-concern warning. Received a second Nasdaq deficiency notice on Sept 1, 2026, for failing to maintain the $1.00 minimum bid price

CEO Shahan Ohanessian and his wife control ~78% of voting power through SSO, LLC, making the company a 'controlled company' with limited minority shareholder protections. This governance risk aligns with the company's repeated compliance failures

Traditional IPO filing on Nasdaq with a Directed Share Program for employees, indicating insider confidence. No pricing terms disclosed yet, but as a pure IPO (not a resale), it avoids the dilution overhang seen in other filings

Changed name from Nukkleus to T3 Defense Inc. (Jan 2, 2024) and acquired Nimbus Drones Technologies in Jan 2026, signaling a pivot to defense. However, the company has no operational track record, government contracts, or security clearances—making the growth narrative highly speculative [NEUTRAL/BEARISH]

Pivoting to a Gen-3 HALO device and acquiring PONM software platform, but has no international revenue in H1 2026 and stopped selling its Gen-1 device in the US. This suggests a complete product transition with zero near-term revenue visibility

The S-1 resale of up to 5.1M shares (64% of outstanding) is one of the most extreme dilutive filings in the pipeline. Existing shareholders face catastrophic dilution if all shares are sold, and the company has no proceeds from this offering

Negative working capital of ~$131M and a stockholders' deficit of $19M, combined with $7.2M in net operating losses over six months. The company's survival hinges on an ELOC facility and cash-positive subsidiaries, both of which are uncertain

Nasdaq delisting hearing scheduled for September 1, 2026, for failing to meet both bid price and stockholders' equity ($1.52M vs $2.5M required). A negative outcome could trigger a liquidity event and complete loss of market access

Second Nasdaq deficiency notice on Sept 1, 2026, after regaining compliance on May 21, 2026. The stock has been volatile and below $1.00 multiple times, with a compliance deadline of Feb 28, 2027. Chronic non-compliance signals structural weakness

$109.2M accumulated deficit with negative working capital of $1.7M. As a newly listed company (Jan 30, 2026), this level of financial distress so early in its public life is a red flag

Despite the name change and drone acquisition, the company has zero government contracts, no security clearances, and no operational history in defense. The transformation appears narrative-driven rather than execution-driven

The S-1 does not disclose the number of shares or price range, leaving significant uncertainty about valuation and market reception. As an emerging growth company, volatility around pricing is expected

Recorded no international revenue in H1 2026, despite operating in the medical device space where global expansion is typical. Revenue comes only from legacy Gen-1 licensing and electrode sales in the US

As the only clean, traditional IPO in the pipeline, Oura represents a potential high-quality listing. The Directed Share Program for employees indicates insider alignment. Monitor for pricing terms—if priced attractively, it could offer a rare IPO pop in an otherwise distressed pipeline

The warrants with a $266.25 exercise price are deep out-of-the-money. If the company executes on its defense pivot or secures contracts, these warrants could become highly leveraged plays. However, the underlying risk is extreme

The company has initiated a pivotal clinical trial for its Gen-3 HALO device. If the trial succeeds and the company resolves its Nasdaq delisting, the stock could re-rate significantly from distressed levels. Entry point near liquidation value if trial data is positive

With CEO control at 78%, the stock trades at a significant governance discount. If the company ever addresses governance concerns (e.g., by reducing voting power), the stock could see a re-rating. However, this is a long-shot catalyst

The acquisition of Nimbus Drones in Jan 2026 positions the company in the high-growth defense drone market. If the company can secure any government contract, the narrative could shift rapidly. Monitor for contract announcements

With a compliance deadline of Feb 28, 2027, the company has ~6 months to engineer a reverse stock split or other means to meet the $1.00 bid price. Such events often create short-term trading opportunities

As an EGC, Oura can confidentially file and reduce disclosure requirements, potentially speeding the IPO timeline. If it lists before year-end 2026, it could benefit from seasonal IPO demand

4 out of 5 filings are from distressed companies with negative working capital, going-concern warnings, or Nasdaq compliance issues. The pipeline is heavily skewed toward low-quality issuers, raising concerns about underwriting standards and investor protection

2 of 5 filings are resale registrations by selling stockholders that generate zero proceeds for the company (Nukkleus, VenHub). This pattern suggests companies are using equity to pay vendors/convert debt rather than raise growth capital

Nexalin and VenHub both received Nasdaq deficiency notices on the same day (Sept 1, 2026). This clustering suggests broader market volatility is hitting micro-cap listings, potentially triggering a wave of delistings in the coming months

VenHub's 78% CEO/insider voting control is a pattern seen in many distressed micro-cap IPOs. This structure often leads to minority shareholder abuse and makes delisting or bankruptcy resolutions more painful for outsiders

Both Nukkleus (fintech to defense) and Nexalin (Gen-1 to Gen-3) are undergoing complete business transformations. These pivots introduce binary risk—success or total failure—with limited middle ground, making them unsuitable for most portfolios

None of the 5 filings provided meaningful forward revenue or earnings guidance. This absence of visibility is unusual for IPOs and suggests even issuers lack confidence in their near-term prospects

The September 1, 2026, delisting hearing is the most immediate event. A positive outcome (extension/compliance plan) could trigger a relief rally; a negative ruling could lead to OTC trading and significant losses. Watch for SEC filing post-hearing

The second deficiency notice on Sept 1, 2026, with a Feb 28, 2027 deadline. Watch for reverse stock split announcements or other compliance attempts. CEO's 78% control means any vote on a split is almost certain to pass

The second tranche of the Feb 2026 $10M private placement is contingent on stock price >$1.00 and average trading value >$900K. If conditions aren't met, the company will rely on its ELOC facility—watch for utilization update

As the only clean IPO, its pricing terms (shares, price range, valuation) will set the tone for the broader IPO market. Announcement expected in weeks following Sept 3 filing

Pivotal trial for the device is ongoing. Data readout could be a major catalyst. The timing is not specified in the filing, so monitor for updates

The S-1 resale creates significant overhang. Watch for selling volume and price action post-effective date. If the stock holds above $1.00, it could signal absorption; if it drops, it could trigger the private placement conditions

With an accumulated deficit of $109.2M and going-concern warning, watch for any missed filing deadlines or auditor resignations that could accelerate the company's decline

The pivot to defense via Nimbus Drones acquisition is speculative without contracts. Watch for any announcements of government or commercial drone deals